Skip to main content
TipRanks
Go Ultimate75% OFF

BioStem Technologies (BSEM) Stock Price & Analysis

316 Followers

BSEM Stock Chart & Stats

$1.05-$0.25(-19.23%)
At close: 4:00 PM EST
$1$2$3$4Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$0.90 - $1.25
52-Week Range
$0.90 - $8.40
Previous Close
$1.30
Volume
N/A
Average Volume (3M)
220.59K
Market Cap
$20.14M
Enterprise Value
$55.39M
Total Cash (Recent Filing)
$971.14K
Total Debt (Recent Filing)
$1.17M
Price to Earnings (P/E)
―
Beta
1.88
Next Earnings
Apr 05, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Broader Customer Adoption

Increasing adoption across multiple product lines strengthens customer integration and revenue breadth. Because customers buying more than one line already contribute over half of revenue, deeper product penetration could support retention, cross-selling and more durable commercial growth.

Expanded Hospital Distribution

GPO access expands procurement availability through established hospital contracting channels and can reduce barriers to adoption. Combined with the company’s focus on hospital revenue, this creates a more scalable route for VENDAJE to reach institutional customers over coming quarters.

Planned Margin Improvement

Moving production in-house could improve economics by reducing reliance on current transfer pricing and increasing control over manufacturing. If process validation and regulatory requirements are completed successfully, the planned margin expansion would strengthen operating leverage and future cash-generation potential.

Bears Say

Severe Liquidity Pressure

A sharply reduced cash balance alongside accelerating operating cash use leaves limited financial flexibility while the business remains loss-making. This increases dependence on financing or asset alternatives and could constrain investment, execution and the company’s ability to absorb further setbacks.

Unprofitable Operating Model

Deep current losses indicate that the commercial model is not yet producing sustainable earnings and that performance has deteriorated substantially from profitable 2024 results. Persistent losses could consume capital, weaken financial resilience and make the planned operating improvements harder to deliver.

Margin And Revenue Contraction

Sequential revenue and gross-margin declines show pressure on both demand and unit economics, particularly during the BioTissue transition. Although management expects improvement later, weaker current contribution limits operating leverage and makes near-term progress dependent on successful execution.

BioStem Technologies News

BSEM FAQ

What was BioStem Technologies’s price range in the past 12 months?
BioStem Technologies lowest stock price was $0.90 and its highest was $8.40 in the past 12 months.
What is BioStem Technologies’s market cap?
BioStem Technologies’s market cap is $20.14M.
When is BioStem Technologies’s upcoming earnings report date?
BioStem Technologies’s next earnings report is estimated for Apr 05, 2027 (not yet confirmed), which is in 140 days.
How were BioStem Technologies’s earnings last quarter?
BioStem Technologies released its earnings results on Nov 12, 2026. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.43 by -$0.21.
Is BioStem Technologies overvalued?
According to Wall Street analysts BioStem Technologies’s price is currently Undervalued.
Does BioStem Technologies pay dividends?
BioStem Technologies does not currently pay dividends.
What is BioStem Technologies’s EPS estimate?
BioStem Technologies’s EPS estimate is -0.45.
How many shares outstanding does BioStem Technologies have?
BioStem Technologies has 19,178,630 shares outstanding.
What happened to BioStem Technologies’s price movement after its last earnings report?
BioStem Technologies reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.43. Following the earnings report the stock price went down -19.231%.
Which hedge fund is a major shareholder of BioStem Technologies?
Currently, no hedge funds are holding shares in BSEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology